IPN 60090
Alternative Names: IACS-6274; IPN60090Latest Information Update: 24 Nov 2021
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Developer Ipsen; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics
- Mechanism of Action Glutaminase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-small cell lung cancer; Ovarian cancer; Solid tumours
Most Recent Events
- 04 Jun 2021 Efficacy, safety, pharmacokinetics and pharmacodynamics data from phase I trial in Solid tumours presented at 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)
- 10 Apr 2021 Pharmacodynamics data from a preclinical trial in Cancer presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)
- 10 Apr 2021 University of Texas M. D. Anderson Cancer Center plans a phase Ib trial in Cancer (Combination therapy) in 2021